Switch theme
Sign up to access all valuation multiples
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
2021
n/a
LTM Revenue $0.7M
LTM EBITDA -$26.0M
$10.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Radiopharm Theranostics has a last 12-month revenue of $0.7M and a last 12-month EBITDA of -$26.0M.
In the most recent fiscal year, Radiopharm Theranostics achieved revenue of $0.2M and an EBITDA of -$27.7M.
Radiopharm Theranostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Radiopharm Theranostics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.2M | $0.2M | XXX | XXX | XXX |
| Gross Profit | $6K | $0.2M | XXX | XXX | XXX |
| Gross Margin | 3% | 98% | XXX | XXX | XXX |
| EBITDA | -$19.6M | -$27.7M | XXX | XXX | XXX |
| EBITDA Margin | -10669% | -14732% | XXX | XXX | XXX |
| Net Profit | -$19.1M | -$21.8M | XXX | XXX | XXX |
| Net Margin | -10377% | -11567% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Radiopharm Theranostics's stock price is AUD 0 (or $0).
Radiopharm Theranostics has current market cap of AUD 53.7M (or $33.7M), and EV of AUD 17.2M (or $10.8M).
See Radiopharm Theranostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.8M | $33.7M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Radiopharm Theranostics has market cap of $33.7M and EV of $10.8M.
Radiopharm Theranostics's trades at 14.7x LTM EV/Revenue multiple, and -0.4x LTM EBITDA.
Analysts estimate Radiopharm Theranostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Radiopharm Theranostics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $10.8M | XXX | XXX | XXX |
| EV/Revenue | 20.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRadiopharm Theranostics's NTM/LTM revenue growth is 20%
Radiopharm Theranostics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Radiopharm Theranostics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Radiopharm Theranostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Radiopharm Theranostics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 41% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5141% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5868% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 12338% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Radiopharm Theranostics acquired XXX companies to date.
Last acquisition by Radiopharm Theranostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Radiopharm Theranostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Radiopharm Theranostics founded? | Radiopharm Theranostics was founded in 2021. |
| Where is Radiopharm Theranostics headquartered? | Radiopharm Theranostics is headquartered in Australia. |
| Who is the CEO of Radiopharm Theranostics? | Radiopharm Theranostics's CEO is Mr. Riccardo Canevari. |
| Is Radiopharm Theranostics publicy listed? | Yes, Radiopharm Theranostics is a public company listed on ASX. |
| What is the stock symbol of Radiopharm Theranostics? | Radiopharm Theranostics trades under RAD ticker. |
| When did Radiopharm Theranostics go public? | Radiopharm Theranostics went public in 2021. |
| Who are competitors of Radiopharm Theranostics? | Similar companies to Radiopharm Theranostics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Radiopharm Theranostics? | Radiopharm Theranostics's current market cap is $33.7M |
| What is the current revenue of Radiopharm Theranostics? | Radiopharm Theranostics's last 12-month revenue is $0.7M. |
| What is the current EBITDA of Radiopharm Theranostics? | Radiopharm Theranostics's last 12-month EBITDA is -$26.0M. |
| What is the current EV/Revenue multiple of Radiopharm Theranostics? | Current revenue multiple of Radiopharm Theranostics is 14.7x. |
| What is the current EV/EBITDA multiple of Radiopharm Theranostics? | Current EBITDA multiple of Radiopharm Theranostics is -0.4x. |
| What is the current revenue growth of Radiopharm Theranostics? | Radiopharm Theranostics revenue growth between 2023 and 2024 was 2%. |
| Is Radiopharm Theranostics profitable? | Yes, Radiopharm Theranostics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
